Your Location：Home >Products >Pharmaceutical >161735-79-1
Appearance:powder
Throughput:100|Kilogram|Month
pd_productuse:intermediate
Delivery Time:in stock
Purity:99% purity
Melting point 155-158°C
storage temp. 2-8°C
solubility H2O: ≥20mg/mL
form powder
color white to tan
optical activity [α]/D +15 to +28°, c = 0.6 mg/mL in H2O
CAS DataBase Reference 161735-79-1(CAS DataBase Reference)
Safety Information
Hazard Codes Xn
Risk Statements 22
Safety Statements 24/25
WGK Germany 3
HS Code 29214990
Description Rasagiline mesylate is a potent and selective irreversible monoamine oxidase B (MAO-B) inhibitor launched in 2005 in Israel by Teva as monotherapy in patients with early Parkinson's disease and as adjuvant treatment in moderate-toadvanced disease. Lundbeck will market the drug throughout Europe. Rasagiline is in phase II clinical trials at Teva and Eisai for the treatment of Alzheimer's type dementia.
Chemical Properties White to Off-White Crystalline Solid
Uses A selective irreversible MAO-B inhibitor. Antiparkinsonian
Uses Rasagiline Mesylate is a new MAO-B inhibitor for the treatment of idiopathic Parkinson's disease.
Uses Rasagiline is a selective irreversible MAO-B inhibitor. Rasagiline is an Antiparkinsonian agent.
CAS：1257044-40-8
CAS：881681-00-1
CAS：10010-93-2
CAS：591-64-0
